Cardiac arrest is a devastating condition. In Luxembourg, among an estimated 400 patients resuscitated from out of hospital cardiac arrest every year, few survive in good conditions. Deterioration of neurological function is a frequent sequelae of survivors of cardiac arrest. Being able to predict neurological outcome after cardiac arrest is an unmet need and would be a major breakthrough since it would allow adapting health care to the individual patient and thus improving outcome. Previous experiments from our laboratory suggest that small non-coding RNA molecules, known as microRNAs (miRNAs), may be used to predict neurological outcome after cardiac arrest. Acting inside the cells as regulators of gene expression, miRNAs can also circulate in the bloodstream. In this project, we will take profit of a privileged access to the TTM trial (Target Temperature Management after out-of-hospital cardiac arrest), a multi-center international randomized clinical trial. This trial is the largest trial ever performed on cardiac arrest patients, with 950 patients enrolled. Blood samples and clinical data from these patients will be used to identify a panel of miRNAs able to predict neurological outcome after cardiac arrest. This biomedical research project is translational and fits into the concept of personalized medicine.